Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand’s COOL-AF registry

[1] Kirchhof P(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-2962

[2] Benussi S(2007)Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 857-867

[3] Kotecha D(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 74 104-132

[4] Ahlsson A(2009)Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 1967-1974

[5] Atar D(2013)Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 1107-1115

[6] Casadei B(2016)Prevention of bleeding in patients with atrial fibrillation undergoing PCI N Engl J Med 375 2423-2434

[7] Hart RG(2017)Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation N Engl J Med 377 1513-1524

[8] Pearce LA(2018)An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial Am Heart J 200 17-23

[9] Aguilar MI(2018)Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial Am Heart J 196 105-112

[10] January CT(2000)Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design Scand Cardiovasc J 34 168-171

[1] Kirchhof P(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-2962

[2] Benussi S(2007)Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 857-867

[3] Kotecha D(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 74 104-132

[4] Ahlsson A(2009)Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 1967-1974

[5] Atar D(2013)Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 1107-1115

[6] Casadei B(2016)Prevention of bleeding in patients with atrial fibrillation undergoing PCI N Engl J Med 375 2423-2434

[7] Hart RG(2017)Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation N Engl J Med 377 1513-1524

[8] Pearce LA(2018)An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial Am Heart J 200 17-23

[9] Aguilar MI(2018)Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial Am Heart J 196 105-112

[10] January CT(2000)Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design Scand Cardiovasc J 34 168-171